Cyclosporine analogue molecules modified at amino acid 1 and 3

Abstract

Analogs of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1. ##STR00001##

Claims

1. A compound of Formula L: ##STR00362## wherein: a) R is H or acetyl; b) R1 is a saturated or unsaturated straight or branched aliphatic carbon chain from 2 to 15 carbon atoms in length; c) R2 is selected from the group consisting of: i) an unsubstituted, N-substituted, or N,N-disubstituted amide; ii) a carboxylic acid; iii) a nitrile; iv) an ester; v) a ketone; vi) a hydroxy, dihydroxy, trihydroxy, or polyhydroxy alkyl; vii) a substituted or unsubstituted aryl; viii) a saturated or unsaturated straight or branched aliphatic carbon chain substituted with a substituent selected from the group consisting of a ketone, a hydroxy, a nitrile, a carboxylic acid, an ester, a 1,3-dioxolane, and an oxo; ix) an aromatic group substituted with a substituent selected from the group consisting of a halogen, an ester, and a nitro; and x) a combination of the saturated or unsaturated straight or branched aliphatic carbon chain of viii) and the aromatic group of ix); and d) R23 is unsubstituted C.sub.1-C.sub.3 alkyl.

2. The compound of claim 1, wherein R1-R2 is selected from the group consisting of: ##STR00363## ##STR00364## ##STR00365##

3. The compound of claim 1, wherein R2 is selected from the group consisting of: ##STR00366## wherein: R5 is a saturated or unsaturated straight or branched aliphatic carbon chain between 1 and 10 carbons in length; and R6 is a monohydroxylated, dihydroxylated, trihydroxylated, or polyhydroxylated saturated or unsaturated straight or branched aliphatic carbon chain between 1 and 10 carbons in length.

4. The compound of claim 1, wherein R1 is a saturated or unsaturated straight or branched aliphatic carbon chain from 5 to 8 carbon atoms in length.

5. The compound of claim 1, wherein R is H.

6. The compound of claim 1, wherein R1-R2 is substituted with a substituent selected from the group consisting of a ketone, a hydroxy, a nitrile, an oxo, a carboxylic acid, an ester, and a 1,3-dioxolane.

7. The compound of claim 1, wherein R23 is selected from the group consisting of: CH.sub.3 and CH.sub.2CH.sub.3.

8. The compound of claim 1, wherein the compound comprises the D-epimer of amino acid 3 which is the amino acid to which R23 is attached.

9. The compound of claim 1, wherein R23 is methyl.

10. The compound of claim 1, wherein ##STR00367## in Formula L is selected from the group consisting of: ##STR00368##

11. The compound of claim 1, wherein R1-R2 is at least 6 carbon atoms in length.

12. A compound selected from the group consisting of: TABLE-US-00017 R23 Isomer a) CH.sub.3 L b) CH.sub.3 D c) CH.sub.3 L d) CH.sub.2CH.sub.3 D e) CH.sub.3 D f) CH.sub.3 L g) CH.sub.2CH.sub.3 D h) CH.sub.3 D i) CH.sub.2CH.sub.3 L j) CH.sub.2CH.sub.3 D k) CH.sub.3 L l) CH.sub.3 D m) CH.sub.3 D n) CH.sub.2CH.sub.3 D o) CH.sub.3 D r) CH.sub.3 D s) CH.sub.3 L t) CH.sub.3 D u) CH.sub.3 D v) CH.sub.3 L w) CH.sub.2CH.sub.3 L x) SCH.sub.3 D/L z) (CH.sub.2).sub.3N.sup.+(CH.sub.3).sub.3 D/L aa) D bb) CH.sub.3 D cc) CH.sub.3 L dd) CH.sub.3 L ee) CH.sub.3 D ff) CH.sub.2CH.sub.3 D gg) CH.sub.3 D hh) CH.sub.3 D ii) CH.sub.2CH.sub.3 D jj) CH.sub.3 D wherein: R is ##STR00403## R is H or acetyl, and wherein the isomer is the isomeric form of amino acid 3 which is the amino acid to which R23 is attached.

13. A pharmaceutical composition comprising the compound of claim 1 and one or more pharmaceutical excipients.

14. A method of treating or preventing a cyclophilin mediated disease or injury in a mammal comprising administering the compound of claim 1 to the mammal.

15. The method of claim 14, wherein the disease or injury is mediated by the over-expression of cyclophilin or the disease is a congenital over-expression of cyclophillin.

16. The method of claim 14, wherein the cyclophilin mediated disease or injury is selected from the group consisting of a viral infection; inflammatory disease; cancer; muscular disorder; neurological disorder; and injury associated with ischemia, reperfusion, loss of cellular calcium homeostasis, loss of ionic homeostasis, increase in free radical production, or toxins that induce mitochondrial dysfunction; wherein the viral infection is optionally caused by a virus selected from the group consisting of Human Immunodeficiency Virus, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, SARS-CoV, hCoV-NL63, hCoV-HKU-1, hCoV-OC43, hCOV-229E, coronavirus, feline infectious peritonitis virus, and transmissible gastroenteritis virus; wherein the inflammatory disease is optionally selected from the group consisting of asthma, autoimmune disease, chronic inflammation, chronic prostatitis, glomerulonephritis, hypersensitivity disease, inflammatory bowel disease, sepsis, vascular smooth muscle cell disease, aneurysms, pelvic inflammatory disease, reperfusion injury, rheumatoid arthritis, transplant rejection, and vasculitis; wherein the cancer is optionally selected from the group consisting of small and non-small cell lung cancer, bladder cancer, hepatocellular cancer, pancreatic cancer, breast cancer, glioblastoma, colorectal cancer, squamous cell carcinoma, melanoma, and prostate cancer; wherein the muscular disorder is optionally selected from the group consisting of myocardial reperfusion injury, muscular dystrophy, collagen VI myopathies, Post-cardiac arrest syndrome (PCAS), heart failure, atherosclerosis, and abdominal aortic aneurysm; wherein the neurological disorder is optionally selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple systems atrophy, multiple sclerosis, cerebral palsy, epilepsy, stroke, diabetic neuropathy, amyotrophic lateral sclerosis (Lou Gehrig's Disease), bipolar disorder, excitotoxic injury, hepatic encephalopathy, hypoglycemia, manganese toxicity, neuronal target deprivation, toxic fatty acids, mechanical nerve injury, spinal cord injury, and cerebral injury; and wherein the injury associated with loss of cellular calcium homeostasis is optionally selected from the group consisting of myocardial infarct, stroke, acute hepatotoxicity, cholestasis, and storage/reperfusion injury of transplant organs.

17. The method of claim 16, wherein the toxic fatty acid is arachadonic acid.

18. A process for the preparation of a compound of Formula L: ##STR00404## wherein: a) R is H or acetyl; b) R1 is a saturated or unsaturated straight or branched aliphatic carbon chain from 2 to 15 carbon atoms in length; c) R2 is selected from the group consisting of: i) an unsubstituted, N-substituted, or N,N-disubstituted amide; ii) a carboxylic acid; iii) a nitrile; iv) an ester; v) a ketone; vi) a hydroxy, dihydroxy, trihydroxy, or polyhydroxy alkyl; vii) a substituted or unsubstituted aryl; viii) a saturated or unsaturated straight or branched aliphatic carbon chain substituted with a substituent selected from the group consisting of a ketone, a hydroxy, a nitrile, a carboxylic acid, an ester, a 1,3-dioxolane, and an oxo; ix) an aromatic group substituted with a substituent selected from the group consisting of a halogen, an ester, and a nitro; and x) a combination of the saturated or unsaturated straight or branched aliphatic carbon chain of viii) and the aromatic group of ix); and d) R23 is a saturated or unsaturated straight or branched optionally substituted aliphatic carbon chain, comprising the steps of: 1) reacting cyclosporin-A (CsA) with a basic lithium alkylamide, in the presence of a suitable solvent optionally with LiCl, followed by reaction with a suitable electrophile to generate a compound of Formula 1: ##STR00405## 2) reacting the compound of Formula 1 with Ac.sub.2O in the presence of a suitable solvent to form a compound of Formula 2A: ##STR00406## 3) reacting the compound of Formula 2A with an oxidant to form a compound of Formula 3A: ##STR00407## 4) reacting the compound of Formula 3A with an electrophile to form a compound of Formula 4A: ##STR00408## and 5) optionally deacylating the compound of Formula 4A.

19. The process of claim 18, wherein the preparation of the compound of Formula L comprises the addition of an excess of LiCl in the suitable solvent in step 1) to form predominantly the L-epimer of the compound of Formula L, or the preparation of the compound of Formula L is carried out in the absence of LiCl in the suitable solvent in step 1) to form predominantly the D-epimer of the compound of Formula L, wherein the chiral center of the L-epimer or the D-epimer of the compound of Formula L is the carbon atom to which R23 is attached.

20. The process of claim 18, wherein the basic lithium alkylamide is lithium diisopropylamide.

21. The process of claim 18, wherein the electrophile is selected from the group defined in the following table, to generate the corresponding R23 in the table: TABLE-US-00018 Electrophile R23 methyl iodide CH.sub.3 ethyl iodide CH.sub.2CH.sub.3 allyl bromide CH.sub.2CHCH.sub.2 1,3-diiodopropane CH.sub.2CH.sub.2CH.sub.2l 1,4-diiodobutane (CH.sub.2).sub.3CH.sub.2l trimethylammonium-3-iodopropane (CH.sub.2).sub.3N.sup.+(CH.sub.3).sub.3 hexafluorophosphate propargyl bromide CH.sub.2CCH tert-butyl bromoacetate CH.sub.2CO.sub.2(t-Bu) benzyl bromide CH.sub.2Ph Formaldehyde CH.sub.2OH Acetaldehyde CH(OH)CH.sub.3 Pivalaldehyde CH(OH)(t-Bu) Benzaldehyde CH(OH)Ph carbon dioxide COOH dimethyl disulfide SCH.sub.3 p-tolyl disulfide S(p-Tol)

22. The process of claim 18, wherein R2 is a carboxylic acid and R23 is CH.sub.3.

23. A process for the preparation of the compound of Formula L of claim 1, comprising the steps of: reacting a compound of Formula 1A with dimethylaminopyridine in the presence of a suitable solvent, to form a compound of Formula 2: ##STR00409## optionally followed by formation of an aldehyde of Formula 3: ##STR00410## optionally followed by a Wittig reaction to generate the compound of Formula L, wherein R23 is selected from the group consisting of: CH.sub.3 and CH.sub.2CH.sub.3.

24. A process for the preparation of the compound of Formula L of claim 1, comprising the steps of: reacting a compound of Formula 5 ##STR00411## wherein R1 and R2 are as defined in claim 1, with a basic lithium alkylamide, in the presence of a suitable electrophile in an appropriate solvent to form the compound of Formula L, wherein R23 is unsubstituted C.sub.1-C.sub.3 alkyl.

25. The process of claim 24, wherein the basic lithium alkylamide is lithium diisopropylamide.

26. The process of claim 24, wherein R2 is a carboxylic acid and R23 is CH.sub.3.

27. A compound of Formula L: ##STR00412## wherein: a) R is H or acetyl; b) R1 is a saturated or unsaturated straight or branched aliphatic carbon chain from 2 to 15 carbon atoms in length; c) R2 is selected from the group consisting of: i) an unsubstituted, N-substituted, or N,N-disubstituted amide; ii) a carboxylic acid; iii) a nitrile; iv) an ester; v) a ketone; vi) a hydroxy, dihydroxy, trihydroxy, or polyhydroxy alkyl; vii) a substituted or unsubstituted aryl; viii) a saturated or unsaturated straight or branched aliphatic carbon chain substituted with a substituent selected from the group consisting of a ketone, a hydroxy, a nitrile, a carboxylic acid, an ester, a 1,3-dioxolane, and an oxo; ix) an aromatic group substituted with a substituent selected from the group consisting of a halogen, an ester, and a nitro; and x) a combination of the saturated or unsaturated straight or branched aliphatic carbon chain of viii) and the aromatic group of ix); and d) R23 is a saturated or unsaturated straight or branched optionally substituted aliphatic carbon chain, wherein R1-R2 is at least 6 carbon atoms in length.

28. The compound of claim 27, wherein R1-R2 is selected from the group consisting of: ##STR00413## ##STR00414##

29. The compound of claim 27, wherein R1 is a saturated or unsaturated straight or branched aliphatic carbon chain from 5 to 8 carbon atoms in length.

30. The compound of claim 27, wherein R is H.

31. The compound of claim 27, wherein R1-R2 is substituted with a substituent selected from the group consisting of a ketone, a hydroxy, a nitrile, an oxo, a carboxylic acid, an ester, and a 1,3-dioxolane.

32. The compound of claim 27, wherein R23 is selected from the group consisting of: CH.sub.3, CH.sub.2CH.sub.3, CH.sub.2CHCH.sub.2, CH.sub.2CH.sub.2CH.sub.2I, (CH.sub.2).sub.3CH.sub.2I, (CH.sub.2).sub.3N.sup.+(CH.sub.3).sub.3, CH.sub.2CCH, CH.sub.2CO.sub.2(t-Bu), CH.sub.2Ph, CH.sub.2OH, CH(OH)CH.sub.3, CH(OH)(t-Bu), CH(OH)Ph, COOH, SCH.sub.3, and S(p-Tol).

33. The compound of claim 27, wherein R23 comprises an optionally substituted C.sub.1-C.sub.3 alkyl.

34. The compound of claim 27, wherein R23 is substituted with amino.

35. The compound of claim 27, wherein R23 is C.sub.1-C.sub.3 alkyl and the compound comprises the D-epimer of amino acid 3 which is the amino acid to which R23 is attached.

36. The compound of claim 27, wherein R23 is methyl.

37. The compound of claim 27, wherein ##STR00415## in Formula L is selected from the group consisting of: ##STR00416##

38. The compound of claim 27, wherein R23 is a straight or branched aliphatic carbon chain of 1 to 6 carbons in length.

39. The compound of claim 1, wherein R1-R2 is ##STR00417## and R23 is methyl, and wherein the compound is a D-epimer, wherein the chiral center of the D-epimer is the carbon to which R23 is attached.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

(1) FIGS. 1A, 1B, and 1C depict Table 5 showing cyclophilin A inhibition and immunosuppression of CsA analogs modifies at position 1 and at positions 1 and 3.

DETAILED DESCRIPTION

(2) According to one aspect, a compound of this invention may be administered neat or with a pharmaceutical carrier to a warm-blooded animal in need thereof. The pharmaceutical carrier may be solid or liquid. The compound may be administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral, as used herein, includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.

(3) The pharmaceutical compositions containing the inventive mixture may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs. Compositions intended for oral use may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients may also be manufactured by known methods. The excipients used may be for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, or alginic acid; (3) binding agents such as starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Pat. Nos. 4,256,108; 4,160,452; and 4,265,874 to form osmotic therapeutic tablets for controlled release.

(4) In some cases, formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

(5) Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients may include: (1) suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; or (2) dispersing or wetting agents which may be a naturally-occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxyethylene sorbitan monooleate.

(6) The aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose, aspartame or saccharin.

(7) Oily suspension may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, a fish oil which contains omega 3 fatty acid, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

(8) Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in a mixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, those sweetening, flavoring and coloring agents described above may also be present.

(9) The pharmaceutical compositions containing the inventive mixture may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil such as olive oil or arachis oils, or a mineral oil such as liquid paraffin or a mixture thereof. Suitable emulsifying agents may be (1) naturally-occurring gums such as gum acacia and gum tragacanth, (2) naturally-occurring phosphatides such as soy bean and lecithin, (3) esters or partial ester 30 derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate. The emulsions may also contain sweetening and flavoring agents.

(10) Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol, aspartame or sucrose. Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.

(11) The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or di-glycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

(12) The inventive compound may also be administered in the form of suppositories for rectal administration of the drug. Suitable compositions can be prepared by mixing the compound with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

(13) For topical use, suitable creams, ointments, jellies, solutions or suspensions, etc., which normally are used with cyclosporine may be employed.

(14) In a particularly preferred embodiment, a liquid solution containing a surfactant, ethanol, a lipophilic and/or an amphiphilic solvent as non-active ingredients is used. Specifically, an oral multiple emulsion formula containing the isomeric analogue mixture and the following non-medicinal ingredients: d-alpha Tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS), medium chain triglyceride (MCT) oil, Tween 40, and ethanol is used. A soft gelatin capsule (comprising gelatin, glycerin, water, and sorbitol) containing the compound and the same non-medicinal ingredients as the oral solution may also preferably be used.

(15) It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the nature and severity of the particular disease or condition undergoing therapy.

(16) Methodology

(17) The reactions set out below, are general examples of the chemical reactions able to synthesize the desired compounds modified at amino acid 1 residue (AA1) and amino acid 3 residue (AA3) of CsA. Modifications to AA1 are depicted as:

(18) ##STR00019##
and modifications to AA3 are depicted as

(19) ##STR00020##
both modifications to AA1 and AA3 use reagents that have the requisite chemical properties, and it would be understood by a person skilled in the art that substitutions of certain reactants may be made.

(20) The identity and purity of the prepared compounds were generally established by methodologies including mass spectrometry, HPLC and NMR spectroscopy. Mass spectra (ESI-MS) were measured on a Hewlett Packard 1100 MSD system. NMR spectra were measured on a Varian MercuryPlus 400 MHz spectrometer in deuterated solvents (DMSO for phosphonium salts, benzene for all other compounds). Analytical and preparative reversed phase HPLC was carried out on an Agilent 1100 Series system.

(21) Synthesis of Phosphonium Salt Compounds

(22) Phosphonium salts are prepared through reaction of triphenylphosphine or any other suitable phosphines with alkyl halides (RX; X=Cl, Br, or I). Suitable alkyl halides are any primary or any secondary aliphatic halide of any chain length or molecular weight. These alkyl halides may be branched or unbranched, saturated or unsaturated.

(23) If the reaction is carried out in toluene (Reaction 1), the product precipitates directly from the reaction solution. Unreactive substrates, however, require a more polar solvent such as dimethylformamide (DMF) (Reaction 2) to shorten reaction times and to achieve satisfactory yields.

Reaction 1

(24) ##STR00021##

(25) Where X is a halide (including but not limited to Cl, Br, and I), and R10 is a saturated or unsaturated, straight or branched aliphatic chain, optionally containing a substituent selected from the group of ketones, hydroxyls, nitriles, carboxylic acids, esters and 1,3-dioxolanes; an aromatic group, optionally containing a substituent selected from the group of halides, esters and nitro; or a combination of the aforementioned saturated or unsaturated, straight or branched aliphatic chain and the aforementioned aromatic groups.

Example 1. Synthesis of 404-15

(26) ##STR00022##

(27) As an illustrative example, triphenylphosphine (13 mmol) is dissolved in 50 mL toluene and chloroacetone (10 mmol) is added to give a clear solution. The reaction is stirred under reflux over night. A colorless solid is filtered off, washed with toluene and hexane and dried in vacuum.

(28) Using Reaction 1, the following compounds are further examples of the compounds that may be synthesized.

(29) TABLE-US-00002 Compound Reactant (R10X) Conditions 404-08 benzyl bromide 4 hours at reflux 404-09 methyl iodide RT over night 404-12 4-nitrobenzyl bromide 6 hours at reflux 404-15 chloroacetone reflux over night 404-64 4-fluorobenzyl bromide reflux over night methyl 3- bromomethylbensoate 6 hours at reflux 404-87 3-nitrobenzyl bromide 6 hours at reflux 404-161 1-bromo-2-butanone RT over night 0 404-170 4-bromobutyronitrile reflux over night

(30) Alternatively, suitable phosphonium salts may be synthesized through Reaction 2 as illustrated below:

Reaction 2

(31) ##STR00032##

(32) Where X is a halide (including but not limited to Cl, Br, and I), and R10 is a saturated or unsaturated, straight or branched aliphatic chain, optionally containing a substituent selected from the group of ketones, hydroxyls, nitriles, carboxylic acids, esters and 1,3-dioxolanes; an aromatic group, optionally containing a substituent selected from the group of halides, esters and nitro; or a combination of the aforementioned saturated or unsaturated, straight or branched aliphatic chain and the aforementioned aromatic groups.

Example 2: Synthesis of 404-51

(33) ##STR00033##

(34) As an illustrative example, triphenylphosphine (11 mmol) is dissolved in 10 mL DMF and 4-bromobutyric acid (10 mmol) is added. The reaction is stirred for 7 hours at 110 C. and is then allowed to cool over night. Fifty mL toluene is added and a crystalline, colorless solid is collected by filtration. The product is washed with toluene and hexane and dried in vacuum over night.

(35) If crystallization does not set in after treatment with toluene, the product is extracted with 20 mL MeOH/H.sub.2O (1:1 mixture). The aqueous phase is washed with toluene and hexane and brought to dryness. The residue is stirred with 50 mL ethyl acetate (EtOAc) at reflux temperature for 20-30 min. If a crystalline solid is obtained, the product is collected by filtration, washed with EtOAc and hexane and dried. In case the product is obtained as an oil or gum, the EtOAc is decanted and the remaining product is dried in vacuum.

(36) Using Reaction 2, the following compounds are further examples of the compounds that may be synthesized.

(37) TABLE-US-00003 Compound Reactant (R11X) Conditions 1-bromobutane 6.5 hours at 120 C. 2-bromomethyl-1,3- dioxolane 120 C. over night 404-34 1-bromooctane 110 C. over night 404-51 5-bromovaleric acid 8 hours at 120 C. 404-78 6-bromohexanol 110 C. over night 404-116 4-bromobutyric acid 7 hours at 110 C. 416-01 1-bromohexane 110 C. over night 0 416-02 6-bromohexanoic acid 110 C. over night 419-132 7-bromoheptanenitrile 110 C. over night 419-134 6-chloro-2-hexanone 110 C. over night 419-136 9-bromo-1-nonanol 110 C. over night 420-32 methyl 7-bromohexanoate 110 C. over night 420-78 11-bromoundecanoic acid 110 C. over night 420-80 3-bromopropionitrile 110 C. over night 420-82 8-bromooctanoic acid 110 C. over night 420-90 6-bromohexanenitrile 110 C. over night 420-94 5-chloro-2-pentanone 110 C. over night 0
Wittig Reaction

(38) The Wittig reaction is broadly applicable to a wide range of substrates and reactants. The side chain, which is introduced to the substrate in the reaction, can represent any number of branched and unbranched, saturated and unsaturated aliphatic compounds of variable length (R) and may contain a broad range of functional groups.

(39) In the Wittig reaction, a base, such as potassium tert-butoxide (KOtBu) is used to generate an ylide from a phosphonium salt. The ylide reacts with the carbonyl group of the substrate, CsA-aldehyde, to form an alkene. Phosphonium salts containing a carboxylic acid side chain require at least two equivalents of base to generate the ylide.

Reaction 3: Synthesis of an Acetylated Cyclosporine Analogue Intermediate Using a Phosphonium Salt Compound Through a Wittig Reaction

(40) ##STR00051##

(41) Where X is a halide (including but not limited to Cl, Br, and I), and R12 is a saturated or unsaturated, straight or branched aliphatic chain, optionally containing a substituent selected from the group of ketones, hydroxyls, nitriles, carboxylic acids, esters and 1,3-dioxolanes; an aromatic group, optionally containing a substituent selected from the group of halides, esters and nitro; or a combination of the aforementioned saturated or unsaturated, straight or branched aliphatic chain and the aforementioned aromatic groups.

Example 3: Synthesis of Compound 404-20 Using a Phosphonium Salt Compound Through a Wittig Reaction

(42) ##STR00052##

(43) As an illustrative example, an oven dried 250 mL flask is charged under argon atmosphere with triphenylbutylphosphonium bromide (6.0 mmol) and 40 mL anhydrous tetrahydrofuran (THF). The suspension is cooled to 0 C. and potassium tert-butoxide (6.0 mmol) is added to obtain an orange color. The reaction is stirred at ambient temperature for 1-2 hours, followed by addition of CsA-aldehyde (2.0 mmol, dissolved in 20 mL anhydrous THF). Stirring is continued for 3 hours at room temperature. The reaction is quenched with 10 mL sat. NH.sub.4Cl and 20 mL ice-water. The layers are separated and the aqueous phase is extracted with EtOAc. The organic layers are combined, washed with brine and dried over Na.sub.2SO.sub.4. The solvent is removed and the crude product is purified over silica gel (hexane/acetone 3:1).

(44) Using Reaction 3, the following compounds are further examples of the compounds that may be synthesized.

(45) TABLE-US-00004 MS Compound Starting Material (Na.sup.+) Remarks 404-16 404-09 1252.9 404-19 404-08 1328.9 404-20 404-14 1294.9 0 1373.9 stirred at 60 C. over night 1324.9 stirred at 60 C. for 2 days 404-33 404-29 1325.0 404-40 404-34 1351.2 1295.1 stirred at reflux for 10 days 0 1338.9 2 eq of KOtBu 404-65 404-64 1347.1 1386.9 stirred at RT over night 1374.1 stirred at RT for 2 days 1325.0 2 eq of KOtBu; stirred at RT for 2 days 0 1308.8 stirred at reflux for 15 days 1305.9 stirred at RT over night 1353.0 2 eq of KOtBu 416-09 416-01 1323.1 1381.0 stirred at RT over night 0 1423.1 2 eq of KOtBu 420-89 420-80 1291.9 1381.1 2 eq of KOtBu 420-96 404-78 1338.9 420-101 419-132 1347.9
Deacetylation

Reaction 4: Deacetylation of Acetylated Cyclosporine Analogues

(46) ##STR00099##

(47) Where R12 is a saturated or unsaturated, straight or branched aliphatic chain, optionally containing a substituent selected from the group of ketones, hydroxyls, nitriles, carboxylic acids, esters, amides, acyl-protected amines and 1,3-dioxolanes; an aromatic group, optionally containing a substituent selected from the group of halides, esters, amines and nitro; or a combination of the aforementioned saturated or unsaturated, straight or branched aliphatic chain and the aforementioned aromatic groups.

Example 4: Synthesis of Compound 404-90 Though Deacetylation

(48) ##STR00100##

(49) As an illustrative example, a solution of 404-20 (0.16 mmol) in 10 mL MeOH is combined with a solution of tetramethylammoniumhydroxide pentahydrate (0.47 mmol) in 2 mL H.sub.2O. The mixture is stirred at room temperature for 2 days. The reaction is concentrated in vacuum and 5 mL 120 are added. The reaction is extracted with EtOAc, the extract is washed with brine, dried over Na.sub.2SO.sub.4 and concentrated to dryness. The crude product is purified by reversed phase preparative HPLC.

(50) Purification of deacetylated compounds is generally carried out over silica gel (hexane/acetone 2:1) or by preparative HPLC. In the case of compounds 404-60, 404-137, 416-08, 420-98 and 420-100 (carboxylic acids), the reaction is acidified to pH 2-3 with 1 M HCl prior to extraction.

(51) Using Reaction 4, the following compounds are further examples of the compounds that may be synthesized.

(52) TABLE-US-00005 MS Compound Starting Material (Na.sup.+) 404-22 404-16 1210.9 01 02 404-25 404-19 1287.0 03 04 404-36 404-33 1283.0 05 06 404-44 404-40 1309.1 07 08 404-58 404-57 1257.1 09 0 404-60 404-59 1297.1 404-61 404-56 1255.1 404-66 404-65 1305.1 404-81-1 404-79-1 1331.1 404-81-2 404-79-1 1345.1 0 404-85 404-83 1326.2 404-90 404-20 1253.0 404-96-1 404-94 1333.0 404-96-2 404-94 1347.0 404-97 404-89 1331.9 0 404-125 404-120 1304.0 404-130 404-128 1270.1 404-132 404-129 1298.0 404-137 404-134 1283.0 404-154 404-150 1338.1 0 404-157 404-155 1310.0 404-173 404-172 1268.9 404-194 404-187 1263.9 416-08 416-04 1311.0 416-13 416-09 1281.1 0 420-17 420-08-1 1368.0 420-30-1 420-27 1312.0 420-43 420-40 1324.9 420-47 420-46 1327.0 420-98 420-85 1381 .1 0 420-100 420-92 1339.1 420-102 420-96 1297.0 420-108 420-101 1305.9 420-117 420-109-1 1352.1 420-120 420-110-1 1410.0 0 420-122 420-107-2 1340.0 420-124 420-109-2 1354.0 420-125 420-110-2 1412.0 420-126 420-107-1 1337.9 420-131 420-130 1297.9 0 420-132 420-128-1 1380.0
Hydrogenation of the Double Bond

(53) The double bond can be hydrogenated under atmospheric pressure to obtain the saturated side chain. Functional groups such as hydroxyl, carbonyl and carboxyl are stable under these conditions and do not require protection. R represents either an acetyl group or hydrogen. In the case of ,-unsaturated carbonyl compounds the double bond has to be reduced prior to deacetylation to avoid cyclization through a nucleophilic addition of the free hydroxy group on the activated double bond.

Reaction 5

(54) ##STR00183##

(55) Where R12 is a saturated or unsaturated, straight or branched aliphatic chain, optionally containing a substituent selected from the group of ketones, hydroxyls, nitriles, carboxylic acids, esters, amides, acyl-protected amines and 1,3-dioxolanes; an aromatic group, optionally containing a substituent selected from the group of halides, esters, amines and nitro; or a combination of the aforementioned saturated or unsaturated, straight or branched aliphatic chain and the aforementioned aromatic groups, and R is either a H or an acetyl group.

Example 5: Synthesis of 404-56

(56) ##STR00184##

(57) As an illustrative example, 404-43 (0.34 mmol) is dissolved in 40 mL anhydrous EtOH and 43 mg Pd/C (10%) and 0.2 mL acetic acid are added. The mixture is stirred under hydrogen at atmospheric pressure for 2 days. The reaction is filtered through Celite and is concentrated in vacuum. The crude product is purified by preparative HPLC.

(58) Using Reaction 5, the following compounds are further examples of the compounds that may be synthesized.

(59) TABLE-US-00006 MS Compound Starting Material (Na.sup.+) 404-50 404-25 1289.1 404-56 404-43 1297.0 404-57 404-31 1327.1 0 404-63 404-60 1299.1 404-74 404-66 1307.1 404-92 404-90 1255.1 404-94 404-79 1388.9 404-168 404-134 1326.8 00 404-172 404-163 1310.9 01 02 420-19 416-08 1313.0 03 04 420-46 420-40 1383.1 05 06 420-68 420-134 1326.9 07 08 420-106 420-98 1383.1 09 0 420-111 420-100 1341.0 420-112 420-102 1298.9 420-130 420-123 1340.0
Reduction of the Nitrile Group

(60) Reduction of the nitrile group to the corresponding primary amine can be achieved with nickel boride generated in situ from sodium borohydride (NaBH.sub.4) and nickel(II)chloride (NiCl.sub.2). Addition of a suitable trapping reagent leads to acyl-protected primary amines (carbamates or amides, respectively) and prevents the formation of secondary amines as an undesired side reaction. The double bond is partially reduced under the given conditions and a product mixture is obtained. Both, saturated and unsaturated protected amine compounds were isolated and purified. For reaction 420-123 the mixture was not separated. Instead, the mixture underwent catalytic hydrogenation to produce the fully saturated compound.

Reaction 6

(61) ##STR00217##

(62) Where Acyl is any one of BOC, acetyl, or butyryl, acylating agent is any one of di-tert-butyldicarbonate, acetic anhydride, and butyric anhydride and R1 is a saturated or unsaturated straight chain or branched aliphatic group. It would be understood by one skilled in the art that the acylating agents described above may be replaced with a broad range of acylating agents to produce a similarly broad range of acyl-protected amines.

Example 6: Synthesis of 420-08

(63) ##STR00218##

(64) As an illustrative example, 404-187 (0.257 mmol) is dissolved in 15 mL methanol and cooled to 0 C. Di-tert-butyldicarbonate (0.514 mmol) and nickel(II)chloride (0.025 mmol) are added to give a clear solution. Sodium borohydride (3.85 mmol) is added in portions over 1 hour. The resulting mixture is stirred at ambient temperature over night. Additional sodium borohydride (1.95 mmol) is added at 0 C. and stirring is continued for 3 hours at room temperature. HPLC shows a mixture of 420-08-1 (carbamate compound) and 420-08-2 (carbamate compound with double bond reduced). The reaction is stirred for 30 minutes with diethylenetriamine (0.257 mmol) and is then concentrated in vacuum. The residue is taken up in 75 mL EtOAc, washed with 20 mL sat. NaHCO.sub.3 solution and dried over Na.sub.2SO.sub.4. The solvent is removed in vacuum. The crude product is purified by preparative HPLC.

(65) Using Reaction 6, the following compounds are further examples of the compounds that may be synthesized.

(66) TABLE-US-00007 Pro- tecting MS Compound Starting Material Reagent (Na.sup.+) 0 di-tert- butyldi- carbonate 1410.0 di-tert- butyldi- carbonate 1412.1 butyric anhydride 1379.9 butyric anhydride 1382.1 acetic anhydride 1394.1 0 acetic anhydride 1396.1 di-tert- butyldi- carbonate 1452.1 di-tert- butyldi- carbonate 1454.1 acetic anhydride 1337.9/ 1339.9 butyric anhydride 1422.1 0 butyric anhydride 1424.1 .sup.1 mixture not separated
Amine Deprotection

(67) The BOC protected amine (carbamate) can be converted into the free amine by acidic hydrolysis using trifluoroacetic acid (TFA).

Reaction 7

(68) ##STR00241##

(69) Where R1 is a saturated or unsaturated, straight or branched aliphatic chain, and R is either a H or an acetyl group.

Example 7: Synthesis of 420-23

(70) ##STR00242##

(71) As an illustrative example, 420-17 (0.026 mmol) is dissolved in 4 mL anhydrous DCM and 2 mL trifluoroacetic acid is added at 0 C. The reaction is stirred at room temperature for 3 hours. Twenty 20 mL dichloromethane is added. The reaction mixture is washed with H.sub.2O and sat. NaHCO.sub.3 solution and is dried over Na.sub.2SO.sub.4. The solvent is removed and the crude product is purified by preparative HPLC.

(72) Using Reaction 7, the following compounds are further examples of the compounds that may be synthesized.

(73) TABLE-US-00008 Compound Starting Material MS (M + 1) 420-23 420-17 1246.0 420-25 420-13 1290.0 420-129 420-120 1288.0
Protection of the Amino Group

(74) The free amino function can be protected using a wide range of protecting groups using established methods. A broader range of protecting agents is available compared to the reductive introduction starting from the nitrile. Together, reactions 7 and 8 offer an alternate route to reaction 6 for the preparation of acyl-protected amino compounds.

Reaction 8

(75) ##STR00249##

(76) Where Acyl is any one of BOC, acetyl or butyryl, acylating agent is any one of di-tert-butyldicarbonate, acetic anhydride, butyric anhydride, it would be understood by one skilled in the art that a broad range of acylating agents including, dicarbonates, anhydrides and acyl halides can be employed to produce a broad range of acyl-protected amines, and R1 is a saturated or unsaturated straight chain or branched aliphatic group.

Example 8: Synthesis of 420-27

(77) ##STR00250##

(78) As an illustrative example, 420-25 (0.039 mmol) is dissolved in 3 mL anhydrous pyridine under nitrogen. The reaction is cooled to 0 C. and acetic anhydride (0.59 mmol) is added. The mixture is stirred at ambient temperature overnight. The solvent is removed in vacuum and the residue is taken up in 25 mL EtOAc. The reaction is washed with 210 mL 1 M HCl, 210 mL sat. NaHCO.sub.3 solution and 10 mL brine and is dried over Na.sub.2SO.sub.4. The solvent is removed in vacuum to give the product as a colorless solid.

(79) Deprotection of Aldehyde

(80) The 1,3-dioxolane moiety is converted into an aldehyde function through acidic hydrolysis.

Reaction 9 and Example 9: Synthesis of 404-47

(81) ##STR00251##

(82) As an illustrative example, a solution of 404-33 (0.246 mmol) in 20 mL formic acid is stirred at room temperature for 45 minutes. One hundred mL ice-water and 200 mL sat. NaHCO.sub.3 solution are added slowly to the reaction (strong foaming). The reaction is extracted with 2150 mL EtOAc. The combined extracts are washed with sat. NaHCO.sub.3 solution, water and brine and are dried over Na.sub.2SO.sub.4. The solvent is removed and the product is dried in vacuum.

(83) Reduction of the Nitro Group

(84) The aromatic nitro compound is reduced to the aniline through catalytic hydrogenation. The reaction leads to the reduction of the double bond.

Reaction 10 and Example 10: Synthesis of 404-120

(85) ##STR00252##

(86) As an illustrative example, 404-89 (0.13 mmol) is dissolved in 2 mL ethanol and Raney-Nickel (0.18 g, 50% in H.sub.2O, washed 3 times with ethanol, then suspended in 2 mL ethanol) and 0.1 mL acetic acid are added. The reaction is stirred at room temperature for 2 days. The reaction is filtered through Celite and the filter cake is washed with methanol. The filtrate is brought to dryness. The residue is taken up in EtOAc, washed with NaHCO.sub.3 solution and brine and is dried over Na.sub.2SO.sub.4. The solvent is removed in vacuum. The crude product is purified over silica gel (hexane/acetone 2:1).

(87) Amide Synthesis

(88) Amides are prepared from carboxylic acids by reaction of an amine with the corresponding acid chloride (Reaction 11). The synthesis can also proceed directly from the acid by use of appropriate coupling reagents, such as DCC and HOBt (Reaction 12).

Reaction 11

(89) ##STR00253##

(90) Where R1 is a saturated or unsaturated, straight or branched aliphatic chain, R15 and R16 are independently hydrogen or a saturated or unsaturated, straight or branched aliphatic chain, or where NR15R16 together forms a morpholinyl moiety.

Example 11: Synthesis of 404-85

(91) ##STR00254##

(92) As an illustrative example, 365-73 (0.04 mmol) and thionylchloride (68 mmol) are combined under nitrogen atmosphere and are heated to reflux for 2 hours. The reaction is allowed to cool and is concentrated to dryness. Twenty mL toluene Is added and the reaction is concentrated to dryness again (2 times). The residue is taken up in 5 mL anhydrous toluene and diethylamine (0.48 mmol) is added. The reaction is stirred at room temperature over night. Five mL H.sub.2O are added and the mixture is extracted with 20 mL EtOAc. The extract is washed with brine and dried over Na.sub.2SO.sub.4. The solvent is removed in vacuum and the crude product is purified over silica gel (hexane/acetone 3:1).

(93) Using Reaction 11, the following compounds are further examples of the compounds that may be synthesized.

(94) TABLE-US-00009 Compound Starting Material MS (Na.sup.+) Amine 404-83 365-73 1368.2 diethylamine 1311.9 anhydrous ammonia .sup.1 0 1340.1 Dimethyl- amine .sup.2 .sup.1 passed through reaction for 10 min at 0 C.; .sup.2 2M solution in THF

Reaction 12

(95) ##STR00261##

(96) Where R1 is a saturated or unsaturated, straight or branched aliphatic chain, R15 and R16 are independently hydrogen or a saturated or unsaturated, straight or branched aliphatic chain, or where NR15R16 together forms a morpholinyl moiety.

Example 12: Synthesis of 420-104

(97) ##STR00262##

(98) As an illustrative example, 420-98 (0.078 mmol) is dissolved in 10 mL anhydrous DCM under nitrogen atmosphere. Dicyclohexylcarbodiimide (DCC, 0.117 mmol) and 1-hydroxybenzotriazole hydrate (HOBt, 0.078 mmol) are added at 0 C. and the mixture is stirred for 15 minutes. Dimethylamine (0.78 mmol) is added to give a clear, colorless solution. The cooling bath is removed after 15 minutes and stirring is continued at ambient temperature for 5 days. The reaction is transferred to a separatory funnel and 20 mL DCM and 10 mL 0.5 M HCl are added. The organic layer is taken off, dried over Na.sub.2SO.sub.4 and concentrated to dryness. The residue is taken up in 10 mL acetonitrile. Undissolved solid is filtered off and the filtrate is concentrated in vacuum. The crude product is purified by preparative HPLC.

(99) Using Reaction 12, the following compounds are further examples of the compounds that may be synthesized.

(100) TABLE-US-00010 MS Compound Starting Material (Na.sup.+) Amine 1380.1 Dimethyl- amine .sup.2 1352.1 Dimethyl- amine .sup.2 1324.1 Dimethyl- amine .sup.2 404-162 416-08 1379.9 Morpholine 0 1309.8 anhydrous ammonia .sup.1 404-178 404-137 1323.9 Propylamine 1408.1 Dimethyl- amine .sup.2 1366.0 Dimethyl- amine .sup.2 0 1338.0 anhydrous ammonia .sup.1 .sup.1 passed through reaction for 10 min at 0 C.; .sup.2 2M solution in THF
Esterification

(101) Carboxylic acid esters are prepared from the corresponding carboxylic acids and an alcohol either using acidic catalysis (Reaction 13) or coupling reagents (DCC and DMAP, Reaction 14).

Reaction 13

(102) ##STR00281##

(103) Where R1 is a saturated or unsaturated, straight or branched aliphatic chain, and R17 is a saturated or unsaturated, straight or branched aliphatic chain, optionally containing a halogen or hydroxyl substituent.

Example 13: Synthesis of 404-171

(104) ##STR00282##

(105) As an illustrative example, a mixture of 404-60 (0.059 mmol), 4 mL EtOH and 2 L conc. H.sub.2SO.sub.4 is heated to reflux for 4 hours. The solvent is evaporated and the residue is taken up in acetonitrile. The crude product is purified by preparative HPLC.

(106) Using Reaction 13, the following compounds are further examples of the compounds that may be synthesized.

(107) TABLE-US-00011 Compound Starting Material MS (Na.sup.+) Reagent 404-171 404-60 1368.2 ethanol 1311.9 ethylene glycol .sup.1 420-103 420-98 1409.1 ethanol 420-113 420-100 1366.9 ethanol 0 .sup.1 3 hours at 90 C.; product extracted with EtOAc

Reaction 14

(108) ##STR00291##

(109) Where R1 is a saturated or unsaturated, straight or branched aliphatic chain, and R17 is a saturated or unsaturated, straight or branched aliphatic chain, optionally containing a halogen or hydroxyl substituent.

Example 14: 420-24

(110) ##STR00292##

(111) As an illustrative example, 404-60 (0.053 mmol) is dissolved in 4 mL anhydrous DCM and cooled to 0 C. under nitrogen atmosphere. Dimethylaminopyridine (DMAP, 0.005 mmol), 2-fluoropropanol (0.27 mmol) and dicyclohexylcarbodiimide (DCC, 0.058 mmol) are added and the reaction is stirred for 15 min at 0 C. The cooling bath is removed and stirring is continued over night at ambient temperature. 20 mL DCM are added, the reaction is then washed with H.sub.2O and evaporated to dryness. The residue is taken up in 10 mL acetonitrile and filtered. The filtrate is concentrated in vacuum. The crude product is purified by preparative HPLC.

(112) Alcohols

(113) Besides direct synthesis in the Wittig reaction, alcohols are obtained through a number of reactions. Reduction of a carbonyl group with sodium borohydride leads to primary (starting from aldehyde) or secondary (starting from ketone) alcohols, respectively.

(114) Oxidation of a double bond through the hydroboration method can lead to a mixture of isomers. The reaction proceeds predominantly in anti-Markovnikov orientation. In the case of a terminal olefin the primary alcohol is the main product.

(115) An olefin can be converted into a diol through oxidation with hydrogen peroxide. Reaction of a carbonyl compound with a Grignard reagent leads to secondary (starting from aldehyde) and tertiary (starting from ketone) alcohols. This method allows for an extension of the carbon chain.

Reaction 15

(116) ##STR00293##

(117) Where R is a H or acetyl, R1 is a saturated or unsaturated, straight or branched aliphatic chain, and R20 is a saturated or unsaturated, straight or branched aliphatic chain.

Example 15: Synthesis of 404-98

(118) ##STR00294##

(119) As an illustrative example, 404-61 (0.0365 mmol) is dissolved in 4.5 mL anhydrous EtOH under nitrogen atmosphere. Sodium borohydride (0.15 mmol, suspended in 0.5 mL anhydrous EtOH) is added at 0 C. and the resulting mixture is stirred at ambient temperature over night. Additional sodium borohydride (0.08 mmol) is added and stirring is continued over night. The reaction is quenched with 5 mL 1 M HCl under ice-bath cooling and is extracted with EtOAc. The extract is washed with brine, dried over Na.sub.2SO.sub.4 and concentrated to dryness. The crude product is purified by preparative HPLC.

(120) Using Reaction 15, the following compounds are further examples of the compounds that may be synthesized.

(121) TABLE-US-00012 Compound Starting Material MS (Na.sup.+) 404-98 404-61 1256.9 404-195 404-173 1271.0 404-198 404-172 1313.0 00 420-09 404-56 1298.9 01 02

Reaction 16

(122) ##STR00303##

(123) Where R1 is a saturated or unsaturated, straight or branched aliphatic chain.

Example 16: Synthesis of 420-28-1

(124) ##STR00304##

(125) As an illustrative example, 404-16 (0.081 mmol) is dissolved under nitrogen atmosphere in 4 mL anhydrous THF. The reaction is cooled to 0 C. and BH.sub.3.THF (1 M sol. in THF, 0.06 mmol) is added. The reaction is stirred at room temperature over night. HPLC shows the reaction is incomplete. Additional BH.sub.3.THF (0.5 mmol) is added and stirring is continued for 4 hours at room temperature. The reaction is cooled to 0 C. and 10 mL 1 M NaOH and 0.30 mL 30% hydrogen peroxide solution are added. The mixture is stirred at room temperature over night. The reaction is extracted with 25 mL EtOAc. The extract is washed with brine, dried over Na.sub.2SO.sub.4 and concentrated to dryness. The product is purified by preparative HPLC.

Reaction 17

(126) ##STR00305##

(127) Where R1 is a saturated or unsaturated, straight or branched aliphatic chain, R is either a H or an acetyl group.

Example 17: Synthesis of 420-49

(128) ##STR00306##

(129) As an illustrative example, 420-49 (0.037 mmol) is dissolved under argon atmosphere in 5 mL anhydrous THF. The reaction is cooled to 70 C. and allylmagnesium chloride (1 M sol. in THF, 0.22 mmol) is added. The reaction is stirred for 15 minutes at 70 C. and is then allowed to come to room temperature. After 90 minutes the reaction is quenched with sat. NH.sub.4Cl solution. The reaction is extracted with 25 mL EtOAc. The extract is washed with brine, dried over Na.sub.2SO.sub.4 and concentrated to dryness. The product is purified by preparative HPLC. A mixture of acetylated and deacetylated compound is obtained.

Reaction 18

(130) ##STR00307##

(131) Where R1 is a saturated or unsaturated, straight or branched aliphatic chain, and R23 is a saturated or unsaturated, straight or branched aliphatic chain.

Example 18: Synthesis of 404-126

(132) ##STR00308##

(133) As an illustrative example, 404-16 (0.054 mmol) is dissolved in 1 mL formic acid and hydrogen peroxide (30% aqueous solution, 0.52 mmol) is added. The reaction is stirred at room temperature over night and is then concentrated to dryness. The residue is dissolved in 25 mL EtOAc, washed with sat. NaHCO.sub.3 solution and dried over Na.sub.2SO.sub.4. The solvent is removed in vacuum. The reaction is taken up in 9 mL THF and 3 mL 1 M NaOH, and is stirred for 4 hours at room temperature. The solvent is removed and the residue is partitioned between 25 mL EtOAc and 5 mL H.sub.2O. The organic layer is washed with brine and dried over Na.sub.2SO.sub.4. The solvent is evaporated and the crude product is purified by preparative HPLC.

Example 19: Modification of Amino Acid 3

(134) CsA undergoes substitution on AA3 as outlined below. Reaction with excess LDA (lithium diisopropylamide) leads to a hexalithio derivative containing four lithium azaenolate units as well as a lithium alkoxide unit on the amino acid 1 side chain and a lithium enolate unit on AA3, respectively. Subsequent reaction with a suitable electrophile generates substitution products on the AA3 (sarcosine) residue. Suitable electrophiles are e.g. alkyl halides, aldehydes, carbon dioxide and alkyl disulfides (Table 1). Both D and L epimers can be obtained, with the relative ratios depending on the reaction conditions. Route A (see below) leads predominantly to the D product, while Route B (addition of excess LiCl) gives mixtures of both epimers.

(135) ##STR00309##

Example 19: Substitution Reaction at AA3 of Cyclosporin A. D and L Stereoisomers are Obtained

(136) Route A: [D-MeSar].sup.3-CsA

(137) An oven dried flask is charged under argon atmosphere with 160 mL anhydrous THF and diisopropylamine (2.07 mL, 14.8 mmol). The solution is cooled to 78 C. and n-butyl lithium (2.5 M in hexane, 5.4 mL, 135 mmol) is added. After stirring for 30 minutes, CsA (2.40 g, 2.0 mmol, dissolved in 40 mL anhydrous THF) is added. The reaction is stirred for 1 hour at 78 C. Additional n-butyl lithium (3.2 mL, 8.0 mmol) is added, followed by addition of methyl iodide (1.25 mL, 20.0 mmol). Stirring is continued at 78 C. far 1.5 hours, and then the reaction is allowed to warm to room temperature over an additional 1.5 hours. 20 mL H.sub.2O are added and the THF is removed in vacuum. Additional 50 mL H.sub.2O are added and an extraction is carried out with 150 mL EtOAc. The extract is washed with brine and dried over Na.sub.2SO.sub.4. The solvent is removed in vacuum and the crude product is purified over silica gel (hexane/acetone 3:1). Yield: 0.74 g (0.61 mmol, 30%).

(138) Route B: [MeSar].sup.3-CsA

(139) A dry 100 mL flask is charged under argon atmosphere with 7.5 mL anhydrous THF and diisopropylamine (0.46 mL, 3.3 mmol). The solution is cooled to 0 C. and n-butyl lithium (1.32 mL, 2.5 M solution in hexane, 3.3 mmol) is added. The reaction is stirred for 20 minutes at 0 C. and is then cooled to 78 C. A solution of CsA (601 mg, 0.5 mmol) and lithium chloride (636 mg, 15 mmol) in 12 mL anhydrous THF is prepared and cooled to 78 C. under argon atmosphere. The LDA solution is then transferred into this mixture through a cannula. The reaction is stirred at 78 C. for 2 hours. Additional n-butyl lithium (1.20 mL, 3.0 mmol) is added, followed by methyl iodide (0.62 mL, 10 mmol). The mixture is allowed to warm to 20 C. and stirred at this temperature for 3 hours. The reaction is allowed to warm to room temperature, quenched with saturated NH.sub.4Cl solution, extracted with EtOAc (220 mL), washed with brine and dried over Na.sub.2SO.sub.4. The solvent is removed in vacuum and the crude product is purified over silica gel (hexane/acetone 3:1). Yield: [L-MeAla.sup.3]-CsA: 302 mg (0.25 mmol, 50%). [D-MeAla.sup.3]-CsA: 76 mg (0.06 mmol, 12%).

(140) TABLE-US-00013 TABLE 1 Examples of possible electrophilee used for the alkylation of the 3- position of Cyclosporin. Electrophile R23.sup.1 Route Remarks methyl iodide CH.sub.3 A/B ethyl iodide CH.sub.2CH.sub.3 A/B allyl bromide CH.sub.2CHCH.sub.2 B 1,3-diiodopropane CH.sub.2CH.sub.2CH.sub.2l B 1,4-diiodobutane (CH.sub.2).sub.3CH.sub.2l B trimethylammonium- (CH.sub.2).sub.3N.sup.+(CH.sub.3).sub.3 B 3-iodopropane hexafluorophosphate propargyl bromide CH.sub.2CCH A 10 equiv electrophile; stirred for 1 h at room temperature after electrophile addition tert-butyl CH.sub.2CO.sub.2(t-Bu) A 5 equiv electrophile; stirred bromoacetate for 1 h at room temperature after electrophile addition benzyl bromide CH.sub.2Ph.sup.2 A 15 equiv LDA and 30 equiv electrophile; stirred for 6 h at 75 C. and 10 h at room temperature after electrophile addition formaldehyde CH.sub.2OH A formaldehyde prepared from paraformaldehyde at 170 C. prior to addition acetaldehyde CH(OH)CH.sub.3 B stirred for 2.5 h at 78 C. after electrophile addition pivalaldehyde CH(OH)(t-Bu).sup.3 B stirred for 70 min at 78 C. after electrophile addition benzaldehyde CH(OH)Ph B stirred for 2.5 h at 78 C. after electrophile addition carbon dioxide COOH A CO.sub.2 gas passed for 15 min through reaction mixture at 78 C.; stirred for 1 h at 78 C. after electrophile addition dimethyl disulfide SCH.sub.3 B stirred for 18 h at 0 C. after electrophile addition p-tolyl disulfide S(p-Tol).sup.4 B stirred for 18 h at 0 C. after electrophile addition .sup.1according to Example 19 .sup.2Ph = phenyl; .sup.3t-Bu = tert-butyl; .sup.4Tol = tolyl.

(141) Examples 20 and 21, set out below, are general examples of the chemical reactions able to synthesize the desired compounds modified at amino acid 1 and 3 of CsA using reagents that have the requisite chemical properties, and it would be understood by a person skilled in the art that substitutions of certain reactants may be made.

Example 20: AA1 Modification of Alkylated CsA

(142) Example 20 provides a synthetic route for the introduction of substituents at the 3-position of CsA prior to modification of the AA1 side-chain. Following the 3-alkylation, a 2 step procedure leads to the acetylated aldehyde (compound 3 in the example below), which is a suitable substrate for the modification of the 1-position via Wittig reaction. This method allows introduction of residues to the AA1 side-chain that have limited stability under the reaction conditions used in steps 1-3, such as strong base and oxidizing agents.

(143) Further examples of compounds prepared using this sequence is summarized in Table 2.

(144) Step 1: Alkylation of AA3 Side-Chain

(145) ##STR00310##

(146) Synthesis is carried out according to Route A or B, respectively, as described above.

(147) Step 2: Acetylation of the Hydroxy-Group on AA1 Side-Chain

(148) ##STR00311##

(149) An oven dried flask is charged under nitrogen with [D-MeSar].sup.3-CsA (1.84 g, 1.51 mmol), N,N-dimethylaminopyridine (19 mg, 0.15 mmol) and 20 mL anhydrous pyridine, followed by acetic anhydride (10 mL, 0.1 mol). The reaction is stirred at ambient temperature over night. The mixture is poured into 100 mL ice-water and is stirred until all ice has melted. A solid is collected by filtration and dried in air. The solid is dissolved in 50 mL EtOAc and is washed with 1 M HCl (2), sat. NaHCO.sub.3 solution and brine. The organic phase is dried over Na.sub.2SO.sub.4 and evaporated. The crude product is purified over silica gel (hexane/EtOAc/MeOH 10:10:0.5).

(150) Step 3: Aldehyde Formation

(151) ##STR00312##

(152) To a flask containing compound 2 (800 mg, 0.636 mmol) are added 10 mL dioxane and 10 mL H.sub.2O. NaIO.sub.4 (544 mg, 2.54 mmol) and OsO.sub.4 (7.9 mM solution in water/dioxane 1:1, 4.05 mL, 32 mmol) are added and the reaction is stirred at room temperature over night 75 mL H.sub.2O is added and the reaction is extracted with 325 mL EtOAc. The extracts are washed with water, sat. NaHCO.sub.3 solution, water and brine (25 mL each) and are dried over MgSO.sub.4. The solvent is removed in vacuum and the crude product is purified over silica gel (hexane/EtOAc 3:1).

(153) Step 4: Wittig

(154) Reaction

(155) ##STR00313##

(156) An oven dried flask Is charged under argon atmosphere with triphenyl-6-hexanoic acid phosphonium bromide (90 mg, 0.195 mmol) and 5 mL anhydrous THF. Potassium t-butoxide (1 M solution in THF, 0.39 mL, 0.39 mmol) is added at 0 C. and the solution is stirred for 30 minutes to give a bright orange color. Compound 3 (81 mg, 0.065 mmol, dissolved in 1 mL anhydrous THF) is added to the reaction drop-wise and stirring is continued at room temperature over night. The reaction is quenched with sat. NH.sub.4Cl solution and is extracted with EtOAc. The extract is washed with brine and dried over Na.sub.2SO.sub.4. The solvent is removed in vacuum and the crude product is purified over silica gel (toluene/acetone 3:1).

(157) Step 5: Deacetylation

(158) ##STR00314##

(159) Compound 4 (30 mg, 0.022 mmol) is dissolved in 2 mL methanol and 0.5 mL water and tetramethylammonium hydroxide pentahydrate (12 mg, 0.066 mmol) Is added. The reaction is stirred at room temperature for several days until HPLC confirms deprotection is complete. The reaction is acidified to pH 2 with 1 M HCl and concentrated in a vacuum. The residue is taken up in EtOAc, is washed with water and dried over Na.sub.2SO.sub.4. The solvent is evaporated and the crude product is purified by preparative HPLC.

(160) ##STR00315##
Schematic Representation of 1,3-Modified Cyclosporin Derivatives.

(161) Using the method of Example 20, the following compounds are further examples of the compounds that may be synthesized (X and Y in reference to the above schematic representation; and reference of R in X is to indicate attachment of structure to AA1 of CsA).

(162) TABLE-US-00014 TABLE 2 Compound X R23 Isomer MS (Na.sup.+) 431-13 CH.sub.3 L 1296.8 414-64 CH.sub.3 D 1325.0 431-19 CH.sub.3 L 1324.8 431-40 CH.sub.2CH.sub.3 D 1338.8 440-02 0 CH.sub.3 D 1327.1 431-20 CH.sub.3 L 1326.9 440-13 CH.sub.2CH.sub.3 D 1341.1 431-21 CH.sub.3 D 1277.9 431-44 CH.sub.2CH.sub.3 L 1291.9 440-14 CH.sub.2CH.sub.3 D 1292.0 431-136 CH.sub.3 L 1283.1 440-24 CH.sub.3 D 1283.1 440-10-1 CH.sub.3 D 1270.9 440-22-1 CH.sub.2CH.sub.3 D 1285.0 440-20 0 CH.sub.3 D 1397.2
Alkylation of AA1 Modified Compounds

(163) Reaction 21 introduces substituents to the AA3 residue of compounds previously modified on the AA1 side-chain. In addition to the groups available through Reaction 19, this route allows the introduction of substituents at AA3 that are unstable under the reaction conditions used in Reaction 20, e.g. a thiomethyl residue could undergo oxidation during the formation of the aldehyde in step 3 of this method.

Example 21

(164) ##STR00331##

(165) A dry 25 mL flask is charged under argon atmosphere with 1.5 mL anhydrous THF and diisopropylamine (87 L, 0.62 mmol). The solution is cooled to 0 C. and n-butyl lithium (2.5 M in hexane, 0.25 mL, 0.62 mmol) is added. The mixture is stirred for 20 minutes at 0 C. and is ten cooled to 70 C. The clear LDA solution is transferred into a solution of 404-76 (118 mg, 0.095 mmol) and lithium chloride (120 mg, 2.84 mmol) in 1.5 mL anhydrous THF at 70 C. Stirring is continued for 2 hours at 70 C. Additional n-butyl lithium (0.23 mL, 0.58 mmol) is added, followed by methyl iodide (118 L, 1.89 mmol). The reaction is allowed to warm to 20 C. and is kept at this temperature over night. The reaction is quenched with sat. NH.sub.4Cl solution and is extracted with EtOAc. The extract is washed with brine, dried over Na.sub.2SO.sub.4 and evaporated to dryness. The crude product is purified over silica gel (hexane/acetone 3:1.fwdarw.2:1).

(166) TABLE-US-00015 TABLE 3 Examples of compounds prepared by Method 21 (X and Y according to FIG. 3; and refperence of R in X is to indicate attachment of structure to AA1 of CsA). Compound X R23 Isomer MS (Na.sup.+) 420-176-1 CH.sub.3 D 1284.9 420-176-2 CH.sub.3 L 1284.9 420-177-1 CH.sub.3 D 1298.8 420-177-2 CH.sub.3 L 1298.8 420-180-1 CH.sub.3 D 1302.8 420-182-1 CH.sub.3 D 1270.8 420-182-2 CH.sub.3 L 1270.8 420-186 CH.sub.2CH.sub.3 L 1409.0 431-42 0 SCH.sub.3 D/L .sup.1 1328.8 440-03 SCH.sub.3 D 1319.1 440-78 (CH.sub.2).sub.3N.sup.+(CH.sub.3).sub.3 D/L .sup.1 .sup.1359.9 .sup.2 440-34-3 D 1416.2 440-36 CH.sub.3 D 1251.1 .sup.1 isomers not separated; .sup.2 m.sup.+ signal.

(167) Additional modifications to the functional groups at AA1 (or AA3, respectively) residue can be carried out to obtain various derivative compounds, such as esters, amides, alcohols etc. Saturated compounds can be obtained by reducing the double bond created in the Wittig reaction.

Example 22: Amide Formation from Carboxylic AcidSynthesis of 440-08

(168) ##STR00346##

(169) 440-02 (48 mg, 0.037 mmol) is dissolved under nitrogen atmosphere in 5 mL anhydrous DCM and cooled to 0 C. Dicyclohexylcarbodiimide (DCC, 11.6 mg, 0.056 mmol) and 1-hydroxybenzotriazole (HOBt, 5.0 mg, 0.037 mmol) are added and the mixture is stirred for 15 minutes at 0 C. Dimethylamine (2 M solution in THF, 0.19 mL, 0.38 mmol) is added and stirring is continued at room temperature for 3 days. The reaction is diluted with 20 mL DCM and washed with 15 mL 0.5 M HCl. The organic phase is dried over NaSO.sub.4 and then brought to dryness. The crude mixture is purified by preparative HPLC.

Example 23: Ester FormationSynthesis of 440-31

(170) ##STR00347##

(171) 440-20 (30 mg, 0.022 mmol) is dissolved in 4 mL anhydrous EtOH and 2 L of conc. H.sub.2SO.sub.4. The reaction is heated to reflux for 3 hours and is then allowed to cool to room temperature. The reaction is brought to dryness. The crude product is purified by preparative HPLC.

Example 24: Amide Formation from Nitrile Compound (Reversed Amide)Synthesis of 440-15

(172) ##STR00348##

(173) A 50 mL flask is charged under nitrogen with 440-09 (80 mg, 0.061 mmol) and 5 mL MeOH. The reaction is cooled to 0 C. and Ni(II)Cl.sub.2.6H.sub.2O (1.4 mg, 0.006 mmol) and acetic anhydride (19 L, 0.20 mmol) are added. Sodium borohydride (104 mg, 2.75 mmol) is added in 2 batched 2 hours apart. The reaction is then allowed to warm to room temperature and is stirred over night. After the reaction is complete, 7 mL 1 M HCl is added. The solution is concentrated in vacuum to approximately half of its original volume. The resulting mixture is extracted with EtOAc, the extract is washed with sat. NaHCO.sub.3 solution and brine and is dried over Na.sub.2SO.sub.4. The solvent is removed in vacuum. The product, which contains some saturated compound, is used in the following step without further purification.

Example 25: Synthesis of 440-25

(174) ##STR00349##

(175) 440-15 (83 mg, 0.061 mmol) is dissolved in 10 mL anhydrous EtOH. Palladium (10 wt % on Carbon, 8 mg) and 3-4 drops of acetic acid are added. The reaction is hydrogenated under atmospheric pressure at room temperature for several days until complete by HPLC. The reaction is filtered through Celite and the filtrate is evaporated to dryness. The crude product is purified by prep. HPLC and is then subjected to the deacetylation step.

Example 26: Synthesis of 440-32

(176) ##STR00350##

(177) 440-25 (41 mg, 0.03 mmol) is dissolved in 4 mL MeOH and tetramethylammonium hydroxide pentahydrate (16 mg, 0.09 mmol, dissolved in 1 mL H.sub.2O) is added. The reaction is stirred at room temperature for 2 days. The reaction is concentrated in vacuum. 5 mL H.sub.2O is added and the product is extracted with EtOAc. The extract is washed with brine, dried over Na.sub.2SO.sub.4 and evaporated to dryness. The crude product is purified by preparative HPLC.

(178) Table 4: Examples of Derivatives of 1,3-Modified Cyclosporin Compounds Obtained by Reducing the Double Bond Created in the Wittig Reaction (X and Y According to FIG. 3; and Reference of R in X is to Indicate Attachment of Structure to AA1 of CsA).

(179) TABLE-US-00016 Compound X R23 Isomer MS (Na.sup.+) 431-23 CH.sub.3 L 1323.8 431-29 CH.sub.3 L 1393.9 440-08 CH.sub.3 D 1354.1 440-27 CH.sub.2CH.sub.3 D 1368.1 440-23 CH.sub.3 D 1424.2 431-32 CH.sub.3 D 1325.9 431-53 CH.sub.2CH.sub.3 L 1339.9 440-32 CH.sub.2CH.sub.3 D 1340.1 440-10-2 CH.sub.3 D 1285.0 440-22-2 0 CH.sub.2CH.sub.3 D 1299.1 440-31 CH.sub.3 D 1425.2
Cyclophilin A Isomerase Inhibition Assay

(180) An enzymatic assay was used to measure the inhibition of CyP-A activity by 1,3 CsA analogs of the present invention, according to a protocol described in the scientific literature with minor modifications. The assay is based on the ability of CyP-A to catalyze a conformational change in proline-containing peptides from cis to trans isomeric conformations. Briefly, a peptide substrate that includes a nitroanilide moiety was supplied to a reaction mixture containing CyP-A, test compound (CsA analog, CsA, or dimethylsulfoxide vehicle), and a second enzyme, alpha-chymotrypsin. Each test compound was tested at 10 concentrations in triplicate or quadruplicate. The peptide was converted from the cis conformation to the trans conformation both by non-catalytic and CyP catalytic processes. The trans isomer of the peptide, but not the cis isomer, is a substrate for alpha-chymotrypsin. Alpha-chymotrypsin immediately cleaved nitroanilide from the rest of the peptide, and free nitroanilide accumulated at a rate proportional to cis-trans isomerization. Since free nitroanilide is a colored product, its accumulation was quantified by measuring its absorbance with a spectrophotometer. Nitroanilide accumulation was measured for 6 minutes, and first order rate constants for each reaction were calculated using Graphpad Prism software. The CyP-A catalytic rate constant of each reaction was determined by subtracting the non-catalytic rate constant (derived from the reaction without CyP-A) from the total reaction rate constant. Plots of the catalytic rate constants as a function of inhibitor concentrations demonstrated the compounds' potencies, defined by their IC.sub.50 values.

(181) Detailed Protocol

(182) A. Peptide

(183) The assay peptide was N-succinyl-alanine-alanine-proline-phenylalanine-p-nitroanilide. It was dissolved to a concentration of 3 mM in a solution of trifluoroethanolamine and lithium chloride (TFE/LiCl). TFE/LiCl was prepared fresh each day by dissolving lithium chloride in trifluoroethanolamine to a concentration of 17 mg/ml. Following dissolution of LiCl, the water content of the TFE/LiCl solution was reduced by adding heat-dried molecular sieves and gentle mixing the solution for at least 30 minutes. The peptide was then dissolved in TFE/LiCl, and the solution cooled to 4 C.-8 C. prior to the assays. Dissolution of the peptide in dry TFE/LiCl promoted more peptide to exist in the cis conformation at the beginning of each assay reaction. Data analysis showed that approximately 60% of the peptide in our assays began as a c/s isomer which Is consistent with reported data in the scientific literature. In the enzyme reactions the peptide was diluted 20-fold to a final assay concentration of 150 M.

(184) B. Test Compounds

(185) The test compounds consisted of CsA, CsA analogs, or dimethylsulfoxide (DMSO). Stock solutions of CsA and CsA analogs were made by dissolution in DMSO to a concentration of 10 mg/ml in sterile microcentrifuge tubes. Stock solutions were stored at 20 C. when not in use. Further dilutions of the test compounds were made on each day of the assays. DMSO and CsA were tested in every experiment to serve as the vehicle control and reference compound, respectively.

(186) The 10 mg/ml stock solutions of CsA and CsA analogs were diluted with DMSO to 50 M in microcentrifuge tubes, based on the molecular weights of the compounds. Nine 3-fold serial dilutions of each compound in DMSO were then made in a 96-well polystyrene plate. An aliquot of DMSO-solution or DMSO vehicle alone was diluted 50-fold in reaction buffer (see below for recipe) to make final concentrations of CsA or CSA ANALOGs of 1000, 333, 111, 37, 12, 4.1, 1.4, 0.46, 0.15, and 0.05 nM. The reaction buffer solutions were stored at 4 C.-8 C. for at least one hour prior to the assays

(187) C. Reaction Buffer

(188) The starting solution (saline buffer) for the reaction buffer consisted of Hepes 50 mM, sodium chloride 100 mM, and human serum albumin 1 mg/ml, adjusted to pH 8.0 with sodium hydroxide. The saline buffer was stored at 4 C. when not in use. On each assay day bovine alpha-chymotrypsin was dissolved in a volume of saline buffer to a concentration of 1 mg/ml. An aliquot of the alpha-chymotrypsin solution was removed to serve as the noncatalytic control reaction buffer. Recombinant human CyP-A was added to the remainder of the chymotrypsin solution to a concentration of 5 nM. The solution containing alpha-chymotrypsin and CyP-A was designated the reaction buffer and was used for preparation of the reaction solutions.

(189) D. Reaction Protocol

(190) All assay reactions were conducted in a cold room within a temperature range of 4 C.-8 C. All solutions and equipment were stored in the cold room for at least 1 hour prior to the assays. The low temperature was necessary for reactions to proceed at a sufficiently slow rate to measure with the available equipment. The measuring device was a BMG Polarstar microplate reader configured for absorbance readings at OD 405 nm. Reactions were performed in 96-well, flat-bottom, polystyrene assay plates. Each assay run consisted of 12 separate reactions in one row of the plate. Peptide was aliquoted at 5 l per well with a single-channel pipettor in one row of the plate, then the plate placed in the plate holder of the microplate reader. Reactions were begun by dispensing 95 l of reaction buffer into each peptide-containing well using a 12-channel pipettor and mixing each reaction thoroughly by repeat pipetting to ensure uniform dissolution of the peptide. The 12 reactions in each assay run were represented by the following: a) 10 reactions, representing one replicate for each of the 10 concentrations of one test compound (CyP-A in reaction buffer) b) 1 reaction with 5 l DMSO vehicle (CyP-A in reaction buffer) c) 1 reaction with 5 l DMSO vehicle (CyP-A A absent from reaction buffer)

(191) Absorbance recordings were begun immediately after mixing. Approximately 15 seconds elapsed from addition of the reaction buffer to the first OD.sub.405 recording due to mixing time and instrument setup. Subsequent readings were made at 6-second intervals for a total of 60 readings over 360 seconds. Three or four reaction runs were made for each test compound to provide data replicates.

(192) E. Data Analysis

(193) The raw data consisted of a time-dependent increase in OD.sub.405. In the presence of CyP-A and the absence of inhibitor the peptide was completely converted to the trans isomer within approximately 150 seconds as demonstrated by a plateau in the OD.sub.405. OD.sub.405 vs. time data were plotted with Graphpad Prism software and fitted with a one phase exponential equation to derive a first order rate constant K for each reaction. In reactions without CyP-A, the rate constant entirely represented the spontaneous noncatalytic, thermal cis-to-trans isomerization of the peptide and was defined as the noncatalytic rate constant K.sub.0. In reactions containing CyP-A, isomerization occurred both through noncatalytic and enzyme-catalyzed processes. Thus, the rate constant K in CyP-A-containing reactions represented the sum of the noncatalytic rate constant K.sub.0 and the catalytic rate constant K.sub.cat. K.sub.cat was calculated by subtracting K.sub.0 (obtained from the reaction without CyP-A) from the total rate constant K. K.sub.cat typically was 3-fold higher than K.sub.0 in reactions with 5 nM CyP-A, 150 M peptide substrate, and no inhibitor.

(194) Plots of K.sub.cat versus inhibitor concentration were fitted with sigmoidal dose-response nonlinear regressions to demonstrate inhibitor potencies. Software-calculated EC.sub.50 values represented the test compound concentrations that inhibited K.sub.cat by 50%. To normalize for inter-experiment variability in assay conditions, CsA was run in every experiment as a reference compound, and CsA analog potency was expressed as a fold-potency relative to CsA based on EC.sub.50 values. For example, a CsA analog EC.sub.50 that was of CsA represented a 2-fold potency compared to CsA, whereas a CSA analog IC.sub.50 that was 5-fold higher than CsA represented a 0.2-fold potency compared to CsA.

(195) Table 5, shown in the attached Figure, shows cyclophilin A inhibition and immunosuppression of CsA analogs modified at position 1 and at positions 1 and 3 according to the present invention.